Haru Morita

Manufactures biopharmaceuticals

Manufactures beer

Operates as a biopharmaceutical company that develops immune medicines

Provides management and technology consulting services

Functions as a College/University

Develops transformative therapeutics for diseases which are caused by malfunctioning of genes

Part of Modalis Therapeutics Corp., Modalis Therapeutics, Inc. is an American biotechnology company specializing in gene therapies for rare genetic diseases. The company is located in the US. The company develops treatments using its proprietary CRISPR-GNDM® platform, an epigenome editing technology that modulates gene regulatory regions to correct gene regulation errors without altering DNA sequences. Its approach targets severe disorders affecting muscles, the heart, and the central nervous system. Modalis employs a hybrid business model that combines in-house drug development with collaborative partnerships, advancing candidates through discovery and early clinical stages before licensing manufacturing and commercialization rights. The company focuses on diseases with high unmet medical needs, including muscular dystrophies, cardiomyopathies, neurodegenerative diseases, and severe pediatric epilepsy, and its pipeline includes gene therapy candidates for conditions such as LAMA2-related congenital muscular dystrophy, Duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, dilated cardiomyopathy, tauopathies, Angelman syndrome, and Dravet syndrome. Modalis utilizes muscle-specific viral vectors and delivery technologies to enhance targeting and safety, and actively seeks partnerships to expand and optimize its therapeutic pipeline. Haru Morita has been the CEO of the company since 2016.